Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9978488 | 1.00 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL27963679 | 1.00 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL14572731 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL21844009 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL16750045 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL24253076 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL22697281 | 0.84 | TP53 (0.43) | TP53CA2CA1ALDH1A1SLC7A5 | |
| SCHEMBL21844003 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL19090792 | 0.84 | TP53 (0.43) | TP53CA2CA1MMEALDH1A1 | |
| SCHEMBL25091419 | 0.80 | TP53 (0.39) | TP53CA2CA1MMEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | claimed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| CN-117098544-A | Diterpenoid compounds acting on Protein Kinase C (PKC) | K-GEN治疗股份有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. | 2022-12-29 | — | — | US | claimed |
| WO-2022204327-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| EP-4041268-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen, Inc. (US) | 2022-08-17 | — | — | EP | claimed |
| CN-114786697-A | Diterpenoids acting on Protein Kinase C (PKC) | K-GEN股份有限公司 | 2022-07-22 | — | — | CN | claimed |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | TOPO TARGET A/S (DK) | 2010-02-04 | — | — | US | claimed |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2024-08-29 | — | — | US | disclosed |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-GEN THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4351581-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | Victoria Link Limited (NZ) | 2024-04-17 | — | — | EP | disclosed |
| WO-2024064391-A2 | USE OF PROTEIN KINASE C (PKC) ACTIVATING COMPOUNDS AS AN ADJUVANT | K-GEN THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| EP-4313095-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | K-Gen Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20100273789-A1 | AMINOACYL PRODRUGS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | TOPO TARGET A/S (DK) | 2010-02-04 | — | — | US | disclosed |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | ADITECH PHARMA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-7230017-B2 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20060100207-A1 | Dihydropyridinone derivatives | BAYER HEALTHCARE AG (DE) | 2006-05-11 | — | — | US | disclosed |
| US-6376655-B1 | APPLYING EXTERNAL STIMULATION; OPTICAL ANISOTROPY | RISO NATIONAL LABORATORY (DK) | 2002-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100207-A1 | Dihydropyridinone derivatives | TNNI3, DHPS, TNNT2 | TP53 4586/4885CA2 1982/4885CA1 3985/4885 |
| US-20240287123-A1 | ANTIVIRAL NUCLEOSIDE ANALOGUES | EBNA1BP2, RPL35, RPL7 | TP53 1726/4885CA2 4756/4885CA1 4498/4885 |
| US-20100273789-A1 | AMINOACYL PRODRUGS | AADAC, DNPEP, AADAT | TP53 3325/4885CA2 2133/4885CA1 3266/4885 |
| US-20220411362-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCH, PRKCB | TP53 201/4885CA2 2326/4885CA1 3535/4885 |
| US-20080227847-A1 | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use | FAH, SLC16A1, FH | TP53 576/4885CA2 878/4885CA1 2100/4885 |
| US-20100029646-A1 | PRODRUGS OF DIPHENYL OX-INDOL-2-ONE COMPOUNDS | IDO1, IDO2, TDO2 | TP53 121/4885CA2 887/4885CA1 733/4885 |
| US-20240197666-A1 | DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC) | PRKCA, PRKCB, PRKCI | TP53 81/4885CA2 3406/4885CA1 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.